PFB-FDGlu (5-(Pentafluorobenzoylamino)Fluorescein Di-β-D-Glucopyranoside)
Invitrogen™

PFB-FDGlu (5-(Pentafluorobenzoylamino)Fluorescein Di-β-D-Glucopyranoside)

Das ß-Glucosidase-Substrat, 5-(Pentafluorobenzoylamino)Fluorescein di-ß-D-Glucopyranosid (PFB-FDGlu) liefert den grün-fluoreszierenden PFB-F-Farbstoff (Anregung/Emissionsmaxima ∼492/516 nm), der bei der Belastung in Zellen durch PinocytoseWeitere Informationen
Have Questions?
KatalognummerMenge
P11947
auch als P-11947 bezeichnet
5 mg
Katalognummer P11947
auch als P-11947 bezeichnet
Preis (EUR)
920,00
Each
Menge:
5 mg
Preis (EUR)
920,00
Each
Das ß-Glucosidase-Substrat,

5-(Pentafluorobenzoylamino)Fluorescein di-ß-D-Glucopyranosid (PFB-FDGlu)

liefert den grün-fluoreszierenden PFB-F-Farbstoff (Anregung/Emissionsmaxima ∼492/516 nm), der bei der Belastung in Zellen durch Pinocytose zu endosomalen und lysosomalen Kompartimenten zu lokalisieren scheint.
Nur für Forschungszwecke. Nicht zur Verwendung bei diagnostischen Verfahren.
Specifications
ZellpermeabilitätMembrangängig
FarbeGreen
Anregung/Emission492⁄516
Zur Verwendung mit (Geräte)Durchflusszytometer
Marker oder FarbstoffFluorescein
ProdukttypSubstrate
Menge5 mg
VersandbedingungRaumtemperatur
LagerungsbedingungenFreezer (-5°C to -30°C)
SubstratBeta-Galactosidase-Substrat
NachweisverfahrenFluoreszent
FormPowder
Substrate PropertiesChemisches Substrat
SubstrattypBeta-Glucosidase Substrate
Target EnzymeBeta-Glucosidase
Unit SizeEach
Inhalt und Lagerung
Im Gefrierschrank lagern (-5 bis -30 °C).

Zitierungen und Referenzen (16)

Zitierungen und Referenzen
Abstract
Development of screening strategies for the identification of paramylon-degrading enzymes.
Authors:Gissibl A,Care A,Sun A,Hobba G,Nevalainen H,Sunna A
Journal:Journal of industrial microbiology & biotechnology
PubMed ID:30806871
Enzymatic degradation of the β-1,3-glucan paramylon could enable the production of bioactive compounds for healthcare and renewable substrates for biofuels. However, few enzymes have been found to degrade paramylon efficiently and their enzymatic mechanisms remain poorly understood. Thus, the aim of this work was to find paramylon-degrading enzymes and ways ... More
Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson's disease.
Authors:Kim S,Wong YC,Gao F,Krainc D
Journal:Nature communications
PubMed ID:33753743
Mitochondria-lysosome contacts are recently identified sites for mediating crosstalk between both organelles, but their role in normal and diseased human neurons remains unknown. In this study, we demonstrate that mitochondria-lysosome contacts can dynamically form in the soma, axons, and dendrites of human neurons, allowing for their bidirectional crosstalk. Parkinson's disease ... More
Flow Cytometry Measurement of Glucocerebrosidase Activity in Human Monocytes.
Authors:Hughes LP,Halliday GM,Dzamko N
Journal:Bio-protocol
PubMed ID:33659542
Glucocerebrosidase (GCase) is an important enzyme for the metabolism of glycolipids. GCase enzyme deficiency is implicated in human disease and the efficient measurement of GCase activity is important for evaluating the efficacy of therapeutics targeting this enzyme. Existing approaches to measure GCase activity include whole blood mass spectrometry-based assays, where ... More
Tau accumulation in degradative organelles is associated to lysosomal stress.
Authors:Piovesana E,Magrin C,Ciccaldo M,Sola M,Bellotto M,Molinari M,Papin S,Paganetti P
Journal:Scientific reports
PubMed ID:37865674
Neurodegenerative disorders are characterized by the brain deposition of insoluble amyloidogenic proteins, such as α-synuclein or Tau, and the concomitant deterioration of cell functions such as the autophagy-lysosomal pathway (ALP). The ALP is involved in the degradation of intracellular macromolecules including protein aggregates. ALP dysfunction due to inherited defects in ... More
The Parkinson's disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons.
Authors:Jones-Tabah J,He K,Karpilovsky N,Senkevich K,Deyab G,Pietrantonio I,Goiran T,Cousineau Y,Nikanorova D,Goldsmith T,Del Cid Pellitero E,Chen CX,Luo W,You Z,Abdian N,Ahmad J,Ruskey JA,Asayesh F,Spiegelman D,Fahn S,Waters C,Monchi O,Dauvilliers Y,Dupré N,Miliukhina I,Timofeeva A,Emelyanov A,Pchelina S,Greenbaum L,Hassin-Baer S,Alcalay RN,Milnerwood A,Durcan TM,Gan-Or Z,Fon EA
Journal:Molecular neurodegeneration
PubMed ID:39587654
Variants in the CTSB gene encoding the lysosomal hydrolase cathepsin B (catB) are associated with increased risk of Parkinson's disease (PD). However, neither the specific CTSB variants driving these associations nor the functional pathways that link catB to PD pathogenesis have been characterized. CatB activity contributes to lysosomal protein degradation ... More